Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
Published 7 months, 1 week ago
Description
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.